Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Current Leases: 2019-2025

Historic Current Leases for Rhythm Pharmaceuticals (RYTM) over the last 6 years, with Sep 2025 value amounting to $624,000.

  • Rhythm Pharmaceuticals' Current Leases was N/A to $624,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $624,000, marking a year-over-year change of. This contributed to the annual value of $770,000 for FY2023, which is 12.57% up from last year.
  • Rhythm Pharmaceuticals' Current Leases amounted to $624,000 in Q3 2025, which was up 22.35% from $510,000 recorded in Q2 2025.
  • In the past 5 years, Rhythm Pharmaceuticals' Current Leases registered a high of $816,000 during Q2 2024, and its lowest value of $224,000 during Q1 2025.
  • Moreover, its 3-year median value for Current Leases was $726,000 (2023), whereas its average is $657,333.
  • In the last 5 years, Rhythm Pharmaceuticals' Current Leases increased by 13.55% in 2021 and then tumbled by 71.75% in 2025.
  • Quarterly analysis of 5 years shows Rhythm Pharmaceuticals' Current Leases stood at $606,000 in 2021, then grew by 12.87% to $684,000 in 2022, then grew by 12.57% to $770,000 in 2023, then grew by 12.40% to $816,000 in 2024, then tumbled by 37.50% to $624,000 in 2025.
  • Its Current Leases stands at $624,000 for Q3 2025, versus $510,000 for Q2 2025 and $224,000 for Q1 2025.